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M any groups of disorders in psychiatry share common features. 1 Major mental disorders are also not fully discrete, but fade into numerous subsyndromal conditions. Further, the distinction between pathological and nonpathological symptoms is not always distinct. The concept of a diagnostic spectrum has been applied to schizophrenia, 2 depression, 3 autism, 4 and impulsive disorders. 5 Recently, proposals arguing that BDs should be reconceptualized as a spectrum have been increasingly prominent in the literature.
The concept of a BSD is not new: the term has been used to refer to a group of disorders (BD I, BD II, BD not otherwise specified, and cyclothymia) listed in DSM-IV, text revision. 6 However, some writers have recommended a further expansion of the spectrum concept. It has been suggested that many unipolar mood disorders, as well as cases of substance abuse and personality disorder, may fall within an expanded BSD. 3, 7, 8 It has also been suggested that conduct disorder in childhood reflects the same process.
The objective of this investigation was to systematically review the relevant literature to identify evidence for improved clinical outcomes resulting from these proposed diagnostic realignments. The goal was to identify high-level evidence that would strongly support recommendations for altered clinical practice.
In the sphere of medical therapeutics, the concept of levels of evidence has become a standard way of summarizing an evidence base. The Oxford Centre for Evidence-based Medicine "levels of evidence chart" 10 places high-quality RCTs at the highest end of the quality-of-evidence hierarchy (only systematic reviews of statistically homogeneous RCTs rank higher) for therapeutic interventions. Expert opinion falls at the lowest level of evidence. When alternative diagnostic algorithms are proposed, controlled cohort studies can also provide level 1 evidence. 10 In other words, even in the absence of randomization, prospective studies showing improved outcomes resulting from application of alternative diagnostic and clinical decision rules or algorithms can provide high-level evidence supporting changes to practice. Several previous reviews have followed the tradition of validating diagnostic ideas with reference to family history, demographic correlates, biological or psychological tests, environmental risk factors, concurrent symptoms, treatment response, diagnostic stability, and course of illness. 11 These reviews have concluded that an expanded BSD concept is valid. [12] [13] [14] However, a distinction can be drawn between such arguments and any specific proposal for altered clinical practice. As previously emphasized by Kendler, 11 validation of a diagnostic construct depends on how the construct is conceptualized, which is fundamentally a nonempirical issue. As such, diagnostic realignment sometimes occurs in the absence of high-level evidence. Nevertheless, the extent of evidence is an important consideration.
Method
The English-language literature was searched in Ovid MEDLINE using the MeSH term bipolar disorder with the subheading classification (that is, bipolar disorder/cl) cross-referenced against the key word spectrum. Next, the key word phrase bipolar spectrum was cross-referenced against drug treatment (that is, bipolar spectrum/dt) in Ovid and was also used to search the Cochrane Database of Systematic Reviews, the Cochrane Central Register of Controlled Clinical Trials, and the National Institutes of Health Clinical Trials Registry (Figure 1 provides a summary of the search results). There were no prospective cohort studies of clinical outcomes identified and only 2 RCTs. One of these 15 was conducted in symptomatic youth (mean age 10 years) at risk of developing a BD. The trial compared divalproex with placebo, finding no effect. The other 16 used the DSM-IV version of the BSD rather than an expanded concept and was not considered a relevant RCT in Figure 1 . There were 8 RCTs listed in the National Institutes of Health Clinical Trials Registry, but only 2 of these used the term spectrum in a way that went beyond the categories currently in DSM-IV. Both of these studies were listed as being in the recruitment phase, and both were restricted to the child or adolescent age group.
A paper by Ghaemi et al 8 proposed diagnostic criteria for a BSD category. Because of this, a search of the Science Citation Index was used to identify all papers citing this article. Therapeutic studies employing these criteria would have cited this source. Citations (n = 97) to the Ghaemi et al 8 paper were found, but only one was a treatment study. This was a retrospective study using clinical records as a data source 17 and would be classified as level 4 evidence in the Oxford system. 10 The Bipolar Spectrum-A Bridge Too Far?
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Results
Essentially no RCTs or prospective cohort studies comparing outcomes associated with altered diagnostic practices were identified ( Figure 1 ); therefore, our goal became that of describing the literature uncovered in the search. Three prominent themes were identified. The first of these was an idea that there is conceptual continuity between bipolar and unipolar disorders. A second theme consisted of assertions that the diagnostic boundaries of BD should be expanded into domains that might not have previously been considered pathological. Finally, there were arguments in various papers supporting redefinition of other diagnostic categories under the bipolar rubric. We refer to the latter phenomenon as diagnostic expansionism. category. The latter strategy is better described as a redefinition of characterological affective lability from that associated with Axis II diagnoses into the BD (in this case, BD IV) category, consistent with the third theme.
Continuity Between Unipolar and Bipolar Disorders
The idea that MDDs and BDs represent variable expressions of the same underlying condition has been ascribed to Kraepelin's concept of manic-depressive insanity, for example, see Benazzi et al 19 and Akiskal et al. 20 The concept posits that a BSD connects 2 extremes, one being unipolar MDD and the other being classical BD I. This view receives its most practical implementation in scales that purport to measure the extent of bipolarity on a dimensional scale spanning this conceptual dimension. Examples include the Bipolar Affective Disorder Dimension Scale. 14 Another is the Structured Clinical Interview for the Mood Spectrum. 13 The developers of these instruments have typically presented them as a means of augmenting, rather than replacing, categorically distinct diagnoses. In theory, the same approach could be applied to what Blacker and Tsuang 21 called contested boundaries-divisions between various diagnostic categories that may be related, either at the level of phenomenology or etiology, to BDs (for example, secondary mania, schizophrenia, and others). The clinical utility of basing treatment decisions on these scale scores appears not to have been evaluated.
A less formal implementation of a dimensional view of unipolarity-bipolarity is the idea of a depressive mixed state. A depressive mixed state differs from a mixed episode as defined in DSM-IV, and refers to manic symptoms, usually meaning symptoms that can be regarded as overactivity, such as psychomotor agitation that are conceptualized as an intermediate category falling between MDD and a mixed episode as defined in DSM-IV. 19 An implication put forward by some authors is that mood stabilizers should be considered instead of antidepressants in depressed patients with some of these symptoms. 19 However, as noted above, apparently no relevant RCTs or prospective cohort studies have evaluated whether improved outcomes result from this strategy. Therefore, it remains unclear whether there is utility in regarding depressive mixed states as manifestations of BD. Only expert opinion is available to support these recommendations.
A related feature of this literature is the concept of latent bipolarity. Various studies have shown that patients with an early age of onset; highly recurrent depression; medication-induced switching from depression to a hypomanic, manic, or mixed state; or a family history of BD are more likely to later display bipolarity. Such considerations are certainly relevant to clinical practice. However, modification of diagnostic criteria to embrace the concept of latent bipolarity may amount to a double-edged sword. Some such information is relatively accessible (for example, age of onset) but remote, and historical information may be unreliably recalled. 22 Further, information about family history can be unreliable and is sometimes not available. DSM-IV tends to favour more directly accessible diagnostic criteria as a means of ensuring reliability. Adopting a greater emphasis on clinical belief and expectation, as opposed to more directly accessible signs and symptoms, is likely to trade off some aspects of predictive validity with lowered objectivity and reliability. Additional research will be required to determine the approach that has the greatest utility.
Duffy and Grof 23 assert that genetic studies provide some justification for including highly recurrent unipolar MDD in the BSD. This is consistent with evidence from RCTs that lithium is about equivalent to antidepressant medications in reducing relapse rates in recurrent depression. 24 If response to lithium treatment is accepted as a validation standard, then this observation provides support for this specific conception of the BSD.
Expanding Diagnostic Boundaries
In psychiatry, the distinction between normality and psychopathology is never trivial as many of the features of mental disorders occur at an attenuated level of severity and persistence in normal human experience. As a result, psychiatric epidemiology is vulnerable to inflation of prevalence estimates. For example, concerns about the diagnostic boundaries of MDD were raised after increased prevalence estimates emerged in the NCS. 25 These were subsequently attributed largely to distinctions concerning clinical significance. 26 Broadened diagnostic boundaries lead, not surprisingly, to higher prevalence. Prevalence estimates for BDs may also be vulnerable to this sort of inflation. Indeed, applying an expanded definition that included the subsyndromal range of hypomanic symptoms resulted in a revised prevalence estimate in the Epidemiological Catchment Area data set from 1% to 6.4%. 27 Clearly, the breadth of the bipolar category has implications for its prevalence. A corollary to the idea that existing definitions are too narrow is the idea that these definitions lead to unrealistically low prevalence estimates. 12, 28 Although instruments such as the Diagnostic Interview Schedule and the CIDI operationalize existing diagnostic criteria, some reappraisal studies have found that clinicians conducting validation interviews regard many of the bipolar syndromes identified by these instruments as not being clinically significant. 29, 30 These epidemiologic data suggest that manic and hypomanic symptoms blend to an appreciable extent with what may be regarded as normal experience. Thus one could argue that there is a need to carefully constrain diagnostic definitions to what truly constitutes a disorder. Studies that The Bipolar Spectrum-A Bridge Too Far?
The Canadian Journal of Psychiatry, Vol 53, No 11, November 2008 W failed to include reappraisal have reported prevalence rates higher than traditional figures; for example, a Hungarian study by Szádóczky et al 31 reported a prevalence of 5.1%. Other recent studies have conducted reappraisal interviews, but they then have not used the results to adjust their prevalence estimates. In the NCS-R, the positive predictive value of the CIDI for BD II was 41%, implying that less than one-half of those classified by the CIDI as having hypomania were classified as such by a clinician interview. 32 Therefore, the resulting prevalence may have been too high. This study included categories for BD I, BD II, and subthreshold disorders. The most common category was the subthreshold group, at 2.4% leading to a total estimated prevalence of 4.4%. 32 The disagreements about prevalence highlight one of Kendler's 11 nonempirical questions: Is it better to have a broadly defined disorder with high prevalence or a more narrowly defined one with a lower prevalence? With broadened stem questions, reduced duration requirements, and less restrictive symptom requirements, Angst et al 33 reported a BSD prevalence or 23.7%.
However, treating the question of prevalence simply as an issue of threshold-setting is problematic because alterations to the threshold then become powerful determinants of prevalence. It would be valuable to have a more cogent basis for deciding who should receive a diagnosis. Wakefield 34 has proposed that a diagnosis should be characterized both by harm (that is, a sociocultural valuation holding that a health state is a negative one) and by behavioural, psychological, or biological dysfunction in the individual. Dysfunction in this model is taken to represent a failure of an internal mechanism to perform a natural function. 34 Taken together, harm and dysfunction provide an approach to defining what constitutes a disorder. In the BSD literature, widening of diagnostic boundaries potentially runs counter to both principles. Mild hypomanic states are not necessarily negative, for example, see Benazzi's 19 reference to "creative thinking" and "increased goal directed activities" p 936 as hypomanic symptoms. Nor are such episodes necessarily dysfunctional as they may be associated with improved functioning. 19 For example, Akiskal 35 described speaking 3 or more languages, eminence, and creativity as being characteristic of the BSD. These observations have been used to support the idea of an expanded spectrum, but according to the harmful dysfunction model, this may come at the cost of losing important reference points dividing health and disease.
Diagnostic Expansionism
One feature of the literature uncovered in this review was an emphasis by some authors on expansion into territory occupied by other disorders. 36 Perhaps the most significant front in this regard occurs at the interface with Axis II disorders. It has been forcefully suggested that BPD should be removed from the diagnostic classification, and that the affective instability that characterizes these patients is a form of bipolarity. 8 However, there appears to be an absence of data to support this conclusion. Theoretically, reclassification of affective instability could lead to improved outcomes in patients currently classified as having BPD if diagnosis-based decision rules led to better outcomes. However, this review failed to identify any high-level evidence that this is true. A previous literature review by Paris et al 37 led to the assertion that:
1. In part, comorbidity between BDs and BPD is an artifact of definition, and mostly concerns BD II.
2. Patients with BPD have not been shown to respond in any consistent way to mood stabilizers.
3. Family studies suggest that BPD is not related to bipolarity.
4.
Prospective studies fail to show that BPD evolves into BD.
5.
Research is insufficient to establish whether these disorders have a common etiology.
The suggestion that many cases of conduct disorder are early forms of bipolarity 9 suffers from the same difficulties. Long-term follow-up of prepubertal children considered to have BD has not confirmed that they develop into classical cases of the disorder, and there are no RCTs demonstrating that these children benefit from pharmacological treatments known to be effective for classical cases.
Discussion
In summary, the rising popularity of the BSD concept appears to have occurred in the absence of any clear and accepted definition for what the term means, and in the absence of high-level evidence demonstrating its value in clinical practice. These conclusions are partially consistent with those of another recent review, which stated that: "research on the use of mood stabilizers in this soft bipolar spectrum is just starting" and that relevant publications on drug treatment "are more clinician-based or expert based than evidence based." 38 p 85 An accompanying editorial, while favouring the spectrum concept in many respects, echoed their concerns about the level of evidence by concurring that "lack of empirical data invites expert opinion." 36, p 68 It is interesting to speculate about possible reasons for the emergence of this situation. Healy 39 relates pressures to expand the diagnosis to the marketing of medications. However, the issue most often seems to be one of judgment and interpretation, with a key issue being whether the occurrence of clinical features associated with mania or hypomania should be viewed as evidence of bipolarity when they occur in an expanded set of contexts.
It appears that some authors have been willing to assume that therapeutic principles applicable to more well-defined categories (for example, BD I and II) apply equally well to altered and expanded categories. As such, authors in this literature have sometimes gone further than would be expected (in the current evidence-based climate) in putting forward therapeutic recommendations. In epidemiologic terms, this tendency can be viewed as an example of judgment about generalizability. Can results from the existing literature of BD clinical trials be generalized to new or expanded populations redefined as BD or exceeding a threshold on a dimensional measure of bipolarity? This question appears not yet to have been addressed in the literature, despite cautionary statements about the issue published more than a decade ago. 40 In the NCS-R, mood stabilizers, anticonvulsants, and antipsychotic medications were defined as appropriate treatments for BDs. 32 The observation that only 8.1% of subthreshold BD cases were receiving appropriate treatment was highlighted as a public health concern. This amounts to a generalization of knowledge about treatment needs for conventionally defined BDs onto a larger, apparently unstudied, group. Our review indicates that there is a lack of literature suitable for determining the appropriate treatment needs of subthreshold BDs. Further, it has been suspected that a broadening of the BD diagnostic category, leading to greater heterogeneity, might have led to a perceived reduction in the effectiveness of lithium. 41 If there are pressures to expand diagnostic categories, these need to be balanced by more serious efforts to define treatment needs in these expanded categories. The current review found little evidence of such balance in the existing literature.
It is possible that treatment recommendations related to expansion of the BSD have been accepted with a relative lack of criticism because they appear to provide solutions to some particularly frustrating clinical problems. For example, Axis II conditions, especially those in Cluster B, are challenging in clinical practice. The possibility that a mood stabilizing medication may be a definitive solution has obvious appeal. Finally, as some of the Cluster B disorders, particularly BPD, are strongly stigmatized this may provide another motive for redefining them as BDs. Irrespective of the validity of these speculative explanations for the popularity of the spectrum concept, this review helps to clarify that high-level evidence favouring changes to diagnostic and therapeutic practice cannot explain the concept's popularity.
The forcefulness and vigour of the recent literature around the issue of a BSD has created a scientific debate that could turn out to be useful. However, credibility will be threatened if stronger evidence defining the role of broader and softer BD concepts in clinical practice does not emerge. RCTs are urgently needed in this area.
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Résumé : Le spectre bipolaire -un pont trop loin?
Objectifs : Examiner la documentation évaluant les résultats de l'expansion de la catégorie diagnostique du trouble bipolaire (TB). Nous nous sommes particulièrement intéressés à identifier les données probantes de haut niveau sur les résultats cliniques améliorés tels qu'ils étaient documentés par des essais randomisés contrôlés (ERC) ou des études de cohortes.
Méthodes : La documentation en anglais a fait l'objet d'une recherche à l'aide d'Ovid MEDLINE; les études sur le TB étaient recherchées au moyen du mot clé spectre. Nous avons utilisé les bibliographies et d'autres bases de données pour poursuivre cette recherche, quand aucun ERC ou étude de cohorte utile ne pouvait être repéré.
Résultats :
Parmi les recherches dans MEDLINE, les résumés et titres de 86 études ont été examinés, et 48 ont été jugées avoir trait au sujet des troubles du spectre bipolaire (TSB). Aucun ERC ni aucune étude de cohorte prospective évaluant un diagnostic modifié ou des pratiques thérapeutiques n'ont été repérés. La documentation sur les TSB consiste surtout dans des opinions d'experts qui mettent l'accent sur : les divers liens entre les troubles de l'humeur bipolaires et unipolaires; une proposition qu'une plus grande partie de la population, qui ne souffre pas d'un trouble de l'humeur comme le définit le Manuel diagnostique et statistique des troubles mentaux, devrait être diagnostiquée dans la catégorie du TB; et des propositions que des syndromes présentement classés ailleurs devraient être attribués à la catégorie du TB.
Conclusions :
Notre recherche n'a pas réussi à trouver de données probantes de haut niveau démontrant l'utilité clinique des modifications diagnostiques proposées. L'acceptation générale du concept du spectre élargi semble se fonder sur l'interprétation de données épidémiologiques descriptives par des experts renommés.
